YUNNAN BAIYAO(000538) 浙商证券·2025-04-01 15:11Investment Rating - The investment rating for Yunnan Baiyao is maintained as "Buy" [2][6]. Core Views - The company reported a revenue of 40.033 billion yuan for 2024, reflecting a year-on-year increase of 2.36%, and a net profit attributable to shareholders of 4.749 billion yuan, up 16.02% year-on-year, slightly exceeding expectations [6]. - The company is focusing on optimizing its structure and enhancing efficiency, with the industrial segment achieving a revenue of 14.468 billion yuan, a 5.30% increase year-on-year, and further increasing its share of total revenue to 36.14% [6]. - The pharmaceutical segment saw significant growth, with sales of Yunnan Baiyao aerosol products exceeding 2.1 billion yuan, a growth of over 26% year-on-year [6]. - The company is also enhancing its new business divisions, with the medical device segment achieving a revenue of 425 million yuan, a 61% increase year-on-year [6]. - The gross margin for the industrial segment improved to 65.93%, up 1.69 percentage points year-on-year, while operating cash flow increased by 22.68% year-on-year [6]. - The company plans to increase its dividend distribution, with a proposed cash dividend of 11.85 yuan per 10 shares, totaling 2.114 billion yuan, which represents 90.09% of the net profit attributable to shareholders for 2024 [6]. - The strategic plan for 2024-2028 emphasizes both internal and external growth strategies, aiming to enhance operational efficiency and explore new business opportunities [6]. Financial Summary - Revenue projections for 2025, 2026, and 2027 are 41.459 billion yuan, 43.433 billion yuan, and 45.167 billion yuan, respectively, with expected growth rates of 3.56%, 4.76%, and 3.99% [2][6]. - The net profit attributable to shareholders is projected to be 5.181 billion yuan, 5.712 billion yuan, and 6.205 billion yuan for 2025, 2026, and 2027, respectively, with growth rates of 9.09%, 10.24%, and 8.63% [2][6]. - Earnings per share (EPS) are expected to be 2.90 yuan, 3.20 yuan, and 3.48 yuan for the same years, with corresponding price-to-earnings (P/E) ratios of 19.65x, 17.83x, and 16.41x [2][6].